Fate Therapeutics (FATE) Share-based Compensation (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Share-based Compensation came in at $3.9 million in Q1 2026, down 46.77% YoY from $7.4 million in Q1 2025, and down 28.93% on a QoQ basis from $5.5 million in Q4 2025.
Fate Therapeutics (FATE) Share-based Compensation (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Share-based Compensation data on file, last reported at $3.9 million in Q1 2026.
- Quarterly Share-based Compensation fell 46.77% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.5 million (down 43.34% YoY) and the FY2025 annual result came in at $24.9 million, down 39.94% from the prior year.
- Share-based Compensation slipped to $3.9 million in Q1 2026, from $5.5 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $78.1 million in Q4 2022 to a low of $558000.0 in Q1 2024.
- A 5-year average of $14.2 million and a median of $9.6 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation slumped 94.92% — and 2025, when it soared 1222.76%.
- Tracing FATE's Share-based Compensation over 5 years: stood at $78.1 million in 2022, then plunged by 87.86% to $9.5 million in 2023, then declined by 3.75% to $9.1 million in 2024, then tumbled by 39.39% to $5.5 million in 2025, then retreated by 28.93% to $3.9 million in 2026.
- The last three Share-based Compensation figures came in at $3.9 million (Q1 2026), $5.5 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | 3.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.93 Mn |
| Mar 31, 2026 | 3.93 Mn |
| Dec 31, 2025 | 5.53 Mn |
| Dec 31, 2025 | 5.53 Mn |
| Sep 30, 2025 | 4.86 Mn |
| Sep 30, 2025 | 4.86 Mn |
| Jun 30, 2025 | 7.15 Mn |
| Jun 30, 2025 | 7.15 Mn |
| Mar 31, 2025 | 7.38 Mn |
| Mar 31, 2025 | 7.38 Mn |
| Dec 31, 2024 | 9.12 Mn |
| Dec 31, 2024 | 9.12 Mn |
| Sep 30, 2024 | 11.77 Mn |
| Sep 30, 2024 | 11.77 Mn |
| Jun 30, 2024 | 9.63 Mn |
| Jun 30, 2024 | 9.63 Mn |
| Mar 31, 2024 | 558,000.00 |
| Mar 31, 2024 | 558,000.00 |
| Dec 31, 2023 | 9.48 Mn |
| Dec 31, 2023 | 9.48 Mn |